The Impact of Health Delivery Integration on Cancer Outcomes

2022 ◽  
Vol 31 (1) ◽  
pp. 91-108
Author(s):  
Vishnukamal Golla ◽  
Deborah R. Kaye
2007 ◽  
Vol 177 (4S) ◽  
pp. 95-95
Author(s):  
Atreya Dash ◽  
Peng Lee ◽  
Qin Zhou ◽  
Aaron D. Berger ◽  
Jerome Jean-Gilles ◽  
...  

BJS Open ◽  
2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
◽  
Soham Bandyopadhyay

Abstract Introduction Childhood cancers are a leading cause of non-communicable disease deaths for paediatric patients around the world. The COVID-19 pandemic may have impacted on global children’s cancer services, which can have consequences for childhood cancer outcomes. The Global Health Research Group on Children’s Non-Communicable Diseases (Global Children’s NCDs) is currently undertaking the first international study to determine the variation in paediatric cancer management during the COVID-19 pandemic, and the short to medium term impacts on childhood cancer outcomes. Methods and analysis This is a multicentre, international, cohort study that will use routinely collected hospital data in a de-identified and anonymised form. Patients will be recruited consecutively into the study, with a 12 -month follow-up period. Patients will be included if they are below the age of 18 years and undergoing anti-cancer treatment for the following cancers: Acute lymphoblastic leukaemia, Burkitt’s Lymphoma, Hodgkin's lymphoma, Wilms Tumour, Sarcoma, Retinoblastoma, Gliomas, Medulloblastomas and Neuroblastomas. Patients must be newly presented or be undergoing active anti-cancer treatment from the 12th March 2020 to the 12th December 2020. The primary objective of the study is to determine 30- and 90-day all-cause mortality rates. This study will examine the factors that influenced these outcomes. Chi-squared analysis will be used to compare mortality between low and middle-income countries and high-income countries. Multilevel, multivariate logistic regression analysis will be undertaken to identify patient-level and hospital-level factors affecting outcomes with adjustment for confounding factors. Ethics and dissemination At the host centre, this study was deemed to be exempt from ethical committee approval due to the use of anonymised registry data. At other centres, participating collaborators have gained local approvals in accordance with their institutional ethical regulations. Collaborators will be encouraged to present the results locally, nationally, and internationally. The results will be submitted for publication in a peer reviewed journal.


BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017665 ◽  
Author(s):  
Charles Ampong Adjei ◽  
Florence Naab ◽  
Ernestina S Donkor

ObjectiveThis study explored the experiences of people with hepatitis B in the Accra metropolis.DesignThe study employed qualitative exploratory descriptive design with purposive sampling technique. Data were collected through face-to-face interview and transcribed verbatim. The data were analysed using content analysis.SettingsParticipants were recruited from one government and one mission hospital in Ghana.ParticipantsFourteen individuals aged between 26 and 45 years with hepatitis B infection were interviewed.ResultsThe findings of the study showed that people with hepatitis B in the Accra metropolis were unclear about the impact of their infection. Furthermore, they experienced psychological and social problems especially when they were initially informed about their hepatitis B status. Sadness, fear, shock, shame and disbelief were some of the experiences reported by participants. Coping strategies adopted include religiosity, denial and lifestyle modification.ConclusionsIt is, therefore, necessary as a country to integrate hepatitis B counselling into the already existing HIV structures in the health delivery system to offer support for individuals diagnosed with hepatitis B. Furthermore, it is important to draw lessons from the process used in the diagnosis of HIV, particularly in ensuring that people provide consent for being tested.


2020 ◽  
Vol 255 ◽  
pp. 164-171
Author(s):  
David Weithorn ◽  
Vanessa Arientyl ◽  
Ian Solsky ◽  
Goyal Umadat ◽  
Rebecca Levine ◽  
...  

2019 ◽  
Vol 38 (10) ◽  
pp. 2531-2536 ◽  
Author(s):  
Margaret Higgins ◽  
Derek E. Smith ◽  
Dexiang Gao ◽  
Duncan Wilcox ◽  
Nicholas G. Cost ◽  
...  

2020 ◽  
Vol 75 (11) ◽  
pp. 741
Author(s):  
Robert Copeland-Halperin ◽  
Mohammed Al-Sadawi ◽  
Sujata Patil ◽  
Nandini Yadav ◽  
Jennifer E. Liu ◽  
...  

2016 ◽  
Vol 12 (12) ◽  
pp. 1507-1515 ◽  
Author(s):  
Stephen R Grant ◽  
Gary V Walker ◽  
B Ashleigh Guadagnolo ◽  
Matthew Koshy ◽  
Usama Mahmood

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15021-e15021
Author(s):  
Jamie RiChard ◽  
Michael Lipsky ◽  
Michael Whalen ◽  
Piruz Motamedinia ◽  
Julia Finkelstein ◽  
...  

e15021 Background: Studies in breast and prostate surgery show reduced cancer recurrence after regional (RA) versus general anesthesia (GA). Mechanisms include RAÕs reduced post-operative opioid use and cortisol-mediated immunosuppression. RA may be used alone during transurethral resection of bladder tumors (TURBT) and in combination with GA during radical cystectomy (RC). We assess the impact of RA on short-term bladder urothelial cell carcinoma (UCC) recurrence after TURBT or RC. Methods: From 8/2001 and 6/2006 to 6/2011, 151 patients underwent RC and 488 patients underwent TURBT for bladder UCC, respectively. Those with incomplete resection on TURBT were excluded. Anesthesia included RA or GA for TURBT, and GA alone or GA + RA for RC. Multivariate logistic regression was performed to identify significant predictors of biopsy- or radiography-confirmed UCC recurrence. Results: TURBT. Of 252 patients, 211 received GA and 41 received RA during TURBT. Patient and operative characteristics were similar between groups. Recurrence was 56% at 12 months for GA and RA. Multivariate analysis revealed clinical stage to be the only predictor of UCC recurrence (HR=1.8, p<0.0001). Anesthesia had no affect on 6 or 12 month RFS, DSS or OS (see table). RC. GA was used in 114 patients and 37 patients had GA + RA at RC. There were no between group differences in patient or tumor characteristics. After follow-up of 18 months, 25.9% and 21.6% recurred in GA and GA+RA groups, respectively (p>0.05). There were no differences in RFS, DSS, or OS (see Table). Conclusions: Contrary to other malignancies, our data suggest anesthesia type at TURBT or RC does not affect bladder cancer outcomes. Anesthesia modality should be based on patient comorbidities and procedure type. [Table: see text]


2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e18068-e18068
Author(s):  
Hubert Pan ◽  
Gary V. Walker ◽  
Pamela Allen ◽  
Stephen Grant ◽  
Beverly Ashleigh Guadagnolo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document